"Anthony's deep expertise in financial strategy will be instrumental as Vivani advances its pipeline and scales its ...

The fu VANI is set to spin off Cortigent, aiming to sharpen its focus on drug implants and unlock long-term value for both entities. Arbor Realty Trust (ABR) has received quite a bit of attention from ...

The proposed spin-off will establish Cortigent as an independent, publicly traded company, enabling it to pursue specialized research and clinical trials while unlocking greater strategic and ...

Vivani Medical, Inc. VANI recently announced the filing of a Form 10 registration statement with the U.S. Securities and Exchange Commission (“SEC”), marking the first formal step toward spinning off ...

Powered by Money.com - Yahoo may earn commission from the links above. The proposed spin-off will establish Cortigent as an independent, publicly traded company, enabling it to pursue specialized ...

Transaction is anticipated to be completed in third quarter 2025 Planned Cortigent Nasdaq listing intended to drive value for Vivani and Cortigent stockholders Cortigent is developing the Orion ...

ALAMEDA, Calif. - Vivani Medical, Inc. (NASDAQ: VANI), a biopharmaceutical company specializing in long-acting drug implants, announced the filing of a Form 10 registration with the SEC for its ...

Vivani Medical plans to spin off Cortigent, allowing both companies to focus on their specialized therapeutic areas by Q3 2025. Vivani Medical, Inc. has announced plans to spin off its subsidiary ...

Cortigent is developing the Orion ® Visual Cortical Prosthesis System to provide meaningful visual perception to people who are blind Cortigent is developing the Stroke Recovery System to improve ...

Vivani’s CEO, Adam Mendelsohn, Ph.D., noted the importance of this milestone in establishing Cortigent as an independent entity dedicated to pioneering neurostimulation technology. Cortigent’s ...

ALAMEDA, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company ...